Jo A. Van Ginderachter

22.3k citations

148 papers · 10.4k indexed · 4 hit papers · h-index 49

Immunology top 0.1%
- Immune cells in cancer 74
- Immune Cell Function and Interaction 39
- Immunotherapy and Immune Responses 32
- Phagocytosis and Immune Regulation 18
- Immune Response and Inflammation 13
Neurology top 0.5%
Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers 11
Cancer Research top 1%
Molecular Biology top 2%
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 13
Epidemiology
- Trypanosoma species research and implications 10

Co-authors: Patrick De Baetselier Kiavash Movahedi Damya Laoui Jan Van den Bossche Conny Gysemans Alain Beschin Geert Raes Eva Van Overmeire
Cited by: Immunology Neurology Oncology
Partner nations: Belgium United States Germany

In The Last Decade

Jo A. Van Ginderachter

146 papers receiving 10.3k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2019 A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment
2013 Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor Immunity
2010 Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes
2008 Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell–suppressive activity

Peers

Countries citing papers authored by Jo A. Van Ginderachter

Since Specialization

Citations

This map shows the geographic impact of Jo A. Van Ginderachter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jo A. Van Ginderachter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jo A. Van Ginderachter more than expected).

Fields of papers citing papers by Jo A. Van Ginderachter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jo A. Van Ginderachter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jo A. Van Ginderachter. The network helps show where Jo A. Van Ginderachter may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jo A. Van Ginderachter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jo A. Van Ginderachter Line = papers co-authored together Jo A. Van Ginderachter links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Imaging of tumor-associated macrophage dynamics during immunotherapy using a CD163-specific nanobody-based immunotracer Yoline Lauwers,Timo W.M. De Groof,Cécile Vincke,Jolien Van Craenenbroeck,Neema Ahishakiye Jumapili,Romina Mora Barthelmess,Guillaume Courtoy,Wim Waelput,Tessa De Pauw,Geert Raes,Nick Devoogdt,Jo A. Van Ginderachter	2024	7
2	The role of RNA modifications in disease-associated macrophages Camille Huart,Mayuk Saibal Gupta,Jo A. Van Ginderachter	2024	1
3	Peroxiredoxin-1 is an H2O2 safe-guard antioxidant and signalling enzyme in M1 macrophages Daria Ezeriņa,Trung Nghia Vo,Ting Luo,Yvon Elkrim,Anna Escoda Suarez,Gaëtan Herinckx,Didier Vertommen,Damya Laoui,Jo A. Van Ginderachter,Joris Messens	2023	1
4	Whole-mouse clearing and imaging at the cellular level with vDISCO Ruiyao Cai,Zeynep Ilgin Kolabas,Chenchen Pan,Hongcheng Mai,Shan Zhao,Doris Kaltenecker,Fabian F. Voigt,Müge Molbay,Tzu‐Lun Ohn,Cécile Vincke,Mihail Ivilinov Todorov,Fritjof Helmchen,Jo A. Van Ginderachter,Ali Ertürk	2023	38
5	Current status and future expectations of nanobodies in oncology trials Tessa De Pauw,Lynn De Mey,Jens Debacker,Geert Raes,Jo A. Van Ginderachter,Timo W.M. De Groof,Nick Devoogdt	2023	21
6	The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology Isaure Vanmeerbeek,Jannes Govaerts,Raquel S. Laureano,Jenny Sprooten,Stefan Naulaerts,Daniel Borràs,Damya Laoui,Massimiliano Mazzone,Jo A. Van Ginderachter,Abhishek D. Garg	2022	15
7	Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma Development Yannick De Vlaeminck,Stefano Bonelli,Robin Maximilian Awad,Maarten Dewilde,Sabrina Rizzolio,Quentin Lecocq,Evangelia Bolli,Ana Rita Santos,Damya Laoui,Steve Schoonooghe,Luca Tamagnone,Cleo Goyvaerts,Massimiliano Mazzone,Karine Breckpot,Jo A. Van Ginderachter	2020	26
8	A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environmentbreakdown → Hannah Van Hove,Liesbet Martens,Isabelle Scheyltjens,Karen De Vlaminck,Ana Rita Pombo Antunes,Sofie De Prijck,Niels Vandamme,Sebastiaan De Schepper,Gert Van Isterdael,Charlotte L. Scott,Jeroen Aerts,Geert Berx,Guy E. Boeckxstaens,Roosmarijn E. Vandenbroucke,Lars Vereecke,Diederik Moechars,Martin Guilliams,Jo A. Van Ginderachter,Yvan Saeys,Kiavash Movahedi	2019	624
9	Exploiting tumor-associated dendritic cell heterogeneity for novel cancer therapies Jiri Keirsse,Helena Van Damme,Jo A. Van Ginderachter,Damya Laoui	2017	24
10	The Ontogeny and Microenvironmental Regulation of Tumor-Associated Macrophages Kiavash Movahedi,Jo A. Van Ginderachter	2016	45
11	M-CSF and GM-CSF Receptor Signaling Differentially Regulate Monocyte Maturation and Macrophage Polarization in the Tumor Microenvironment Eva Van Overmeire,Benoı̂t Stijlemans,Felix Heymann,Jiri Keirsse,Yannick Morias,Yvon Elkrim,Lea Brys,Chloé Abels,Qods Lahmar,Can Ergen,Lars Vereecke,Frank Tacke,Patrick De Baetselier,Jo A. Van Ginderachter,Damya Laoui	2015	191
12	STAT of the union: Dynamics of distinct tumor‐associated macrophage subsets governed by STAT1 Eva Van Overmeire,Damya Laoui,Jiri Keirsse,Stefano Bonelli,Qods Lahmar,Jo A. Van Ginderachter	2014	12
13	Tumor Hypoxia Does Not Drive Differentiation of Tumor-Associated Macrophages but Rather Fine-Tunes the M2-like Macrophage Population Damya Laoui,Eva Van Overmeire,Giusy Di Conza,Chiara Aldeni,Jiri Keirsse,Yannick Morias,Kiavash Movahedi,Isabelle Houbracken,Elio Schouppe,Yvon Elkrim,Oussama Karroum,Bénédicte F. Jordan,Peter Carmeliet,Conny Gysemans,Patrick De Baetselier,Massimiliano Mazzone,Jo A. Van Ginderachter	2013	338
14	Modulation of CD8+ T-cell activation events by monocytic and granulocytic myeloid-derived suppressor cells Elio Schouppe,Eva Van Overmeire,Damya Laoui,Jiri Keirsse,Jo A. Van Ginderachter	2013	43
15	Nanobody-Based Targeting of the Macrophage Mannose Receptor for Effective In Vivo Imaging of Tumor-Associated Macrophages Kiavash Movahedi,Steve Schoonooghe,Damya Laoui,Isabelle Houbracken,Wim Waelput,Karine Breckpot,Luc Bouwens,Tony Lahoutte,Patrick De Baetselier,Geert Raes,Nick Devoogdt,Jo A. Van Ginderachter	2012	244
16	Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytesbreakdown → Kiavash Movahedi,Damya Laoui,Conny Gysemans,Martijn Baeten,Geert Stangé,Jan Van den Bossche,Matthias Mack,Daniël Pipeleers,Pieter In 'T Veld,Patrick De Baetselier,Jo A. Van Ginderachter	2010	964
17	Functional characterization of in vivo effector CD4+ and CD8+ T cell responses in acute Toxoplasmosis: An interplay of IFN-γ and cytolytic T cells Erik Jongert,Arnaud Lemière,Jo A. Van Ginderachter,Stéphane De Craeye,Kris Huygen,Sushila D’Souza	2010	37
18	IL-10 Dampens TNF/Inducible Nitric Oxide Synthase-Producing Dendritic Cell-Mediated Pathogenicity during Parasitic Infection Martin Guilliams,Kiavash Movahedi,Tom Bosschaerts,Thierry VandenDriessche,Marinee Chuah,Michel Hérin,Abel Acosta‐Sanchez,Ling Ma,Muriel Moser,Jo A. Van Ginderachter,Lea Brys,Patrick De Baetselier,Alain Beschin	2009	101
19	Nitric Oxide-Independent CTL Suppression during Tumor Progression: Association with Arginase-Producing (M2) Myeloid Cells Yuanqing Liu,Jo A. Van Ginderachter,Lea Brys,Patrick De Baetselier,Geert Raes,Anja Geldhof	2003	85
20	B7-1, IFNγ and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma Jo A. Van Ginderachter,YuanQing Liu,Anja Geldhof,Lea Brijs,Kris Thielemans,Patrick De Baetselier,Geert Raes	2000	23

About Jo A. Van Ginderachter

Jo A. Van Ginderachter is a scholar working on Immunology, Oncology and Parasitology, having authored 148 papers that have together received 10.4k indexed citations. Recurring topics across this work include Immune cells in cancer (74 papers), Immune Cell Function and Interaction (39 papers), Immunotherapy and Immune Responses (32 papers), Phagocytosis and Immune Regulation (18 papers), Monoclonal and Polyclonal Antibodies Research (13 papers), Immune Response and Inflammation (13 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Trypanosoma species research and implications (10 papers). The work is most often cited by research in Immunology (6.6k citations), Neurology (1.0k citations) and Oncology (3.2k citations). Jo A. Van Ginderachter has collaborated with scholars based in Belgium, United States and Germany. Frequent co-authors include Patrick De Baetselier, Kiavash Movahedi, Damya Laoui, Jan Van den Bossche, Conny Gysemans, Alain Beschin, Geert Raes, Eva Van Overmeire, Martin Guilliams and Jiri Keirsse.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact